No Data
No Data
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
JonesTrading Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $18
Alto Neuroscience Highlights Data From Precision Psychiatry Platform At ACNP Annual Meeting; Interim Analysis For ALTO-300 Phase 2b Trial In MDD Expected Q1 2025, With Topline Results In H1 2025
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Potential Catalysts and Strategic Focus: Analyzing Alto Neuroscience's Upcoming Trials and Precision Psychiatry Approach
Alto Neuroscience Strengthens Financial Position Amid Increased R&D